CN113876995B - Nanofiber membrane for skin wound and preparation method thereof - Google Patents

Nanofiber membrane for skin wound and preparation method thereof Download PDF

Info

Publication number
CN113876995B
CN113876995B CN202111126685.0A CN202111126685A CN113876995B CN 113876995 B CN113876995 B CN 113876995B CN 202111126685 A CN202111126685 A CN 202111126685A CN 113876995 B CN113876995 B CN 113876995B
Authority
CN
China
Prior art keywords
pbas
aond
solution
composite material
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111126685.0A
Other languages
Chinese (zh)
Other versions
CN113876995A (en
Inventor
张迎
章一新
陈云生
张铮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ninth Peoples Hospital Shanghai Jiaotong University School of Medicine
Original Assignee
Ninth Peoples Hospital Shanghai Jiaotong University School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ninth Peoples Hospital Shanghai Jiaotong University School of Medicine filed Critical Ninth Peoples Hospital Shanghai Jiaotong University School of Medicine
Priority to CN202111126685.0A priority Critical patent/CN113876995B/en
Publication of CN113876995A publication Critical patent/CN113876995A/en
Application granted granted Critical
Publication of CN113876995B publication Critical patent/CN113876995B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/12Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a nanofiber membrane for skin wounds and a preparation method thereof, wherein the nanofiber membrane is of a core-shell structure, and a shell layer material contains gelatin; the core layer material contains polycaprolactone and nano enzyme composite material. The invention utilizes the activities of PBAs nano enzyme, hydrogen peroxide and superoxide enzyme to inhibit the wound inflammation, and antisense oligonucleotide AOND selectively inhibits TGF-beta 1 expression, inhibits the formation of scar and promotes the healing of wound.

Description

Nanofiber membrane for skin wound and preparation method thereof
Technical Field
The invention belongs to the field of functional nanofiber membranes and preparation thereof, and particularly relates to a nanofiber membrane for skin wound surfaces and a preparation method thereof.
Background
During wound healing, signaling pathways are activated that act together to restore the tissue microenvironment, consisting of cells and the extracellular matrix (ECM), including enzymes, cytokines, and growth factors. The process of wound healing comprises four stages: coagulation, inflammation, repair and remodeling stages. Reactive Oxygen Species (ROS), such as hydrogen peroxide, hydroxyl radicals, and superoxide radicals, are generated in excess at the site of injury. Although ROS have important biological functions in the body, excessive reactive oxygen species affect cell proliferation and cause apoptosis through oxidative damage to cell membranes, DNA and proteins, and unresolved inflammation is a major cause of impaired wound healing because they overwhelm the cellular antioxidant system and impede the healing process. Thus, continued oxidative stress at the wound site compromises the function of skin cells (fibroblasts, keratinocytes, etc.), promotes inflammation, necrosis and fibrotic scarring, ultimately delaying the tissue repair process. In mammals, enzymes having ROS-degrading ability such as Catalase (CAT), superoxide dismutase (SOD), glutathione Peroxidase (POD), etc. constitute an antioxidant defense system against intracellular increased ROS.
The nano enzyme is used as a nano material with a high-efficiency catalytic function of natural enzyme characteristics, and has the characteristics of low cost, good stability, high catalytic activity and the like. Nanoenzymes regulate skin wound healing by modulating reactive oxygen species and inhibiting inflammation, reportedly inhibiting inflammatory mediators of Lipopolysaccharide (LPS) -induced macrophages. The Prussian Blue (PB) nanoenzyme with a Metal Organic Framework (MOF) structure not only has the degradation activity of hydrogen peroxide, but also has strong superoxide and peroxide removing capability, and has application potential in wound treatment.
CN110772379A a preparation method of a compound nanometer fibrous membrane of load nanometer enzyme and its wound surface are applied, use nanometer enzyme to balance the active oxygen expression in vivo, achieve the goal of diminishing inflammation and promoting healing, but can only play a weak role to scar hyperplasia, increase and closely relate to fibrosis of the tissue in the scar plastic phase of wound healing, and transforming growth factor TGF-beta 1 expresses and is the main factor that fibrosis regulates and control, the invention can inhibit wound healing TGF-beta 1 over-expression in the scar plastic phase effectively, achieve the function of inhibiting the scar.
Disclosure of Invention
The invention aims to solve the technical problem of providing a nanofiber membrane for skin wounds and a preparation method thereof, and overcoming the defect that scars cannot be effectively inhibited in the prior art.
According to the nanofiber membrane, the nanofiber membrane is of a core-shell structure, wherein a shell layer material contains gelatin; the core layer material contains polycaprolactone and a nano-enzyme composite material.
The nano enzyme composite material is a PBAs/AOND nano enzyme composite material, and specifically comprises the following components: containing inorganic iron salt, inorganic zinc salt, surfactant and K 4 [Fe(CN) 6 ]The raw materials are subjected to solvothermal reaction to obtain a prussian blue analogue PBAs powdery product, and then the prussian blue analogue PBAs powdery product is mixed and stirred with antisense oligonucleotide AOND of TGF-beta 1 to obtain the PBAs/AOND nano enzyme composite material.
The TGF-beta 1 antisense oligonucleotide AOND sequence is specifically 5.
The preparation method of the nanofiber membrane comprises the following steps:
dissolving gelatin in a solvent to obtain a shell solution; mixing polycaprolactone, a PBAs/AOND nano enzyme composite material and a solvent to obtain a core layer solution; and carrying out coaxial electrostatic spinning to obtain the nanofiber membrane.
The preferred mode of the above preparation method is as follows:
the molecular weight of the polycaprolactone is 6-8 ten thousand;
the solvent is hexafluoroisopropanol; the mass concentration of gelatin in the shell layer solution is 5-15%; the mass concentration of polycaprolactone in the core layer solution is 6-15%; the mass concentration of the PBAs/AOND nano enzyme composite material is 0.001-0.1%;
the PBAs/AOND nano enzyme composite material is specifically as follows:
mixing inorganic iron salt solution, inorganic zinc salt solution and surfactant, and adding K 4 [Fe(CN) 6 ]Reacting the solution for 1-60 min at 40-80 ℃, centrifugally washing at 10000-25000 r/min, and freeze-drying to obtain Prussian blue analog PBAs;
mixing the Prussian blue analogue PBAs with AOND, stirring, centrifugally washing at 10000-25000 r/min, and freeze-drying to obtain the PBAs/AOND nano-enzyme composite material.
The inorganic ferric salt is one of ferric chloride, ferric nitrate, ferric sulfate and ferric acetate; the inorganic zinc salt is one of zinc chloride, zinc nitrate, zinc sulfate and zinc acetate; the concentrations of the inorganic ferric salt solution and the inorganic zinc salt solution are both 1-10 mM; the surfactant is polyvinylpyrrolidone PVP and/or ethylene diamine tetraacetic acid EDTA.
The mole ratio of the Prussian blue analogues PBAs to the AOND is 1:10 3 -10 4 (ii) a The stirring is carried out for more than 8 hours at 25 ℃.
The specific technological parameters of the coaxial electrostatic spinning are as follows: the spinning voltage is as follows: 6-20kv, the receiving distance is 6-20cm, the flow rate of the core solution is 0.1-1 mL/min, and the flow rate of the shell solution is 0.1-2 mL/min.
The invention relates to application of the nanofiber membrane in skin wound materials.
The invention can fully utilize the programmability of nucleic acid molecules, and successfully fuse the nucleic acid molecules with Prussian blue analogue metal organic framework Structures (PBAs) through phosphoric acid coordination to prepare the functionalized nano enzyme. The material has good anti-inflammatory performance, and can inhibit tissue inflammation and promote tissue regeneration when used as a wound dressing.
Advantageous effects
The invention coordinates and compounds a phosphorylation TGF-beta 1 antisense nucleotide sequence 5 'GTAGCCTTGGCTCGTG-3' with metal ions in PBAs to obtain a functional nano-enzyme composite material PBAs/AOND, and finally prepares the functional nano-enzyme-loaded fiber membrane with a core-shell structure through coaxial electrostatic spinning. The PBAs nanoenzyme activity of the technology can inhibit wound inflammation, AOND selectively inhibits TGF-beta 1 expression, inhibits scar formation, and promotes wound healing. The preparation method is simple, and the obtained product has good stability and can meet the requirements of clinical application.
The preparation method is simple and can be used for mass preparation. The prepared nano-fiber has good air permeability, good drug-loading performance and stable performance, and the addition of the functional nano-enzyme can promote the rapid healing of wound tissues.
Drawings
FIG. 1 is a scanning electron microscope SEM image of PBAs/AOND in example 1.
Detailed Description
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Further, it should be understood that various changes or modifications of the present invention may be made by those skilled in the art after reading the teaching of the present invention, and such equivalents may fall within the scope of the present invention as defined in the appended claims. The polyvinylpyrrolidone has a molecular weight of 3-5 ten thousand
The molecular weight of polycaprolactone is 6-8 ten thousand
Example 1
(1) The preparation method by the solvothermal method specifically comprises the following steps: respectively preparing ferric chloride solution and zinc acetate solution with concentration of 5mM, and mixing 1mL and 2mL of polyvinylpyrrolidone with concentration of 28mg/mLHomogeneous, 2mL of K at 5mM concentration 4 [Fe(CN) 6 ]Slowly adding the solution into the mixed solution, and reacting at 50 ℃ for 10min to obtain Prussian Blue Analogues (PBAs). Centrifugal washing is carried out at a rotation speed of 20000r/min, and then freeze drying is carried out to obtain the PBAs powdery product.
(2) Dissolving the obtained 10mL of 5nM PBAs and 10mL of 5uM AOND in water, stirring at 25 ℃ for 8 hours, centrifuging and washing with deionized water at the rotating speed of 20000r/min, and freeze-drying to obtain the PBAs/AOND nano-enzyme composite material. (3) Dissolving gelatin in hexafluoroisopropanol to obtain gelatin solution with mass fraction of 8% as shell solution; dissolving polycaprolactone in hexafluoroisopropanol to obtain a polycaprolactone solution with the mass fraction of 10%, and then adding 0.1mg of AOND-PBANPs to obtain a core solution; preparing the nanofiber membrane under the condition of regulating and controlling a spinning process under the conditions that the temperature is 20 ℃ and the humidity is 40%. Co-spinning to obtain PCL/AOND-PBANPs @ GE.
The specific spinning conditions are as follows: voltage 15kv, receiving distance 12cm, flow rate of core 0.1mL/min and flow rate of shell solution 0.2mL/min.
Example 2
(1) The preparation method by the solvothermal method specifically comprises the following steps: the molar ratio is 2:1, 2mL and 1mL of ferric chloride and zinc acetate with the concentration of 8mM respectively, and uniformly mixing with 3mL of 28mg/mL polyvinylpyrrolidone, and 3mL of K with the concentration of 5mM 4 [Fe(CN) 6 ]Slowly adding the solution into the mixed solution, and reacting at 70 deg.C for 30min to obtain Prussian Blue Analogues (PBAs). Centrifugal washing at 15000r/min, and freeze drying to obtain PBAs powder.
(2) And d, dissolving 10mL of 5nM PBAs obtained in the step a and 10mL of 5uM AOND in water, stirring for 10 hours at 25 ℃, centrifuging and washing with deionized water at the rotating speed of 15000r/min, and freeze-drying to obtain the PBAs/AOND nano enzyme composite material.
(3) Dissolving gelatin in hexafluoroisopropanol to obtain a gelatin solution with the mass fraction of 12 percent as a shell solution; dissolving polycaprolactone into hexafluoroisopropanol to obtain a polycaprolactone solution with the mass fraction of 12%, and then adding 0.2mg of AOND-PBANPs to obtain a core solution; preparing the nanofiber membrane under the condition of regulating and controlling a spinning process under the conditions that the temperature is 20 ℃ and the humidity is 40%. Co-spinning to obtain PCL/AOND-PBANPs @ GE.
The specific spinning conditions are as follows: the voltage was 10kv, the receiving distance was 15cm, the flow rate of the core was 0.2mL/min, and the flow rate of the shell solution was 0.2mL/min.
Example 3
(1) The preparation method by the solvothermal method specifically comprises the following steps: ferric chloride and zinc acetate, each with a concentration of 5mM, 1mL each, were mixed with 3mL of 28mg/mL polyvinylpyrrolidone, and 2mL of 5mM K was added 4 [Fe(CN) 6 ]Slowly adding the solution into the mixed solution, and reacting at 70 deg.C for 30min to obtain Prussian Blue Analogues (PBAs). Centrifugal washing at 15000r/min, followed by freeze-drying gave the product as a powder of PBAs.
(2) Dissolving gelatin in hexafluoroisopropanol to obtain gelatin solution with mass fraction of 8% as shell solution; dissolving polycaprolactone in hexafluoroisopropanol to obtain a polycaprolactone solution with the mass fraction of 10%, and then dissolving 0.1mg of PBANPs to obtain a nuclear solution; the nanofiber membrane is prepared under the condition that the temperature is 20 ℃ and the humidity is 40% by regulating and controlling the spinning process. Co-spinning to obtain PCL/AOND-PBANPs @ GE.
The specific spinning conditions are as follows: voltage 15kv, receiving distance 12cm, flow rate of core 0.1mL/min and flow rate of shell solution 0.2mL/min.

Claims (8)

1. The nanofiber membrane is characterized by being of a core-shell structure, wherein a shell layer material contains gelatin; the core layer material contains polycaprolactone and nano enzyme composite material;
the nano enzyme composite material is a PBAs/AOND nano enzyme composite material, and specifically comprises the following components: containing inorganic iron salt, inorganic zinc salt, surfactant and K 4 [Fe(CN) 6 ]The raw materials of (1) are subjected to solvothermal reaction to obtain Prussian blue analogues PBAs, and then the Prussian blue analogues PBAs are mixed and stirred with antisense oligonucleotide AOND to obtain a PBAs/AOND nano enzyme composite material; wherein the antisense oligonucleotide AOND sequence is specifically 5 'GTAGCCTTGGCTCGTG-3'.
2. A method of making the nanofiber membrane of claim 1 comprising:
dissolving gelatin in a solvent to obtain a shell solution; mixing polycaprolactone, a PBAs/AOND nano enzyme composite material and a solvent to obtain a core layer solution; and carrying out coaxial electrostatic spinning to obtain the nanofiber membrane.
3. The production method according to claim 2, wherein the solvents are hexafluoroisopropanol; the mass concentration of gelatin in the shell solution is 5-15%; the mass concentration of polycaprolactone in the core layer solution is 6 to 15 percent; the mass concentration of the PBAs/AOND nano-enzyme composite material is 0.001-0.1%.
4. The preparation method according to claim 2, wherein the PBAs/AOND nanoenzyme composite material is specifically:
mixing inorganic iron salt solution, inorganic zinc salt solution and surfactant, and adding K 4 [Fe(CN) 6 ]Reacting the solution at 40 to 80 ℃ for 1 to 60min, centrifuging, washing, and freeze-drying to obtain Prussian blue analog PBAs;
mixing the Prussian blue analogue PBAs and AOND, stirring, centrifuging, washing, and freeze-drying to obtain the PBAs/AOND nano-enzyme composite material.
5. The preparation method of claim 4, wherein the inorganic ferric salt is one of ferric chloride, ferric nitrate, ferric sulfate and ferric acetate; the inorganic zinc salt is one of zinc chloride, zinc nitrate, zinc sulfate and zinc acetate; the concentrations of the inorganic ferric salt solution and the inorganic zinc salt solution are both 1 to 10mM; the surfactant is polyvinylpyrrolidone PVP and/or ethylene diamine tetraacetic acid EDTA.
6. The preparation method according to claim 2, wherein the mole ratio of the Prussian blue analogues PBAs to AOND is 1:10 3 -10 4 (ii) a The stirring is carried out for more than 8 hours at 25 ℃.
7. The preparation method according to claim 2, wherein the specific process parameters of the coaxial electrostatic spinning are as follows: the spinning voltage is as follows: 6-20kv, the receiving distance is 6-20cm, the flow rate of the core solution is 0.1-1mL/min, and the flow rate of the shell solution is 0.1-2mL/min.
8. Use of the nanofiber membrane of claim 1 in the preparation of a skin wound material.
CN202111126685.0A 2021-09-26 2021-09-26 Nanofiber membrane for skin wound and preparation method thereof Active CN113876995B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111126685.0A CN113876995B (en) 2021-09-26 2021-09-26 Nanofiber membrane for skin wound and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111126685.0A CN113876995B (en) 2021-09-26 2021-09-26 Nanofiber membrane for skin wound and preparation method thereof

Publications (2)

Publication Number Publication Date
CN113876995A CN113876995A (en) 2022-01-04
CN113876995B true CN113876995B (en) 2022-12-02

Family

ID=79006700

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111126685.0A Active CN113876995B (en) 2021-09-26 2021-09-26 Nanofiber membrane for skin wound and preparation method thereof

Country Status (1)

Country Link
CN (1) CN113876995B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737071A1 (en) * 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
CN106075539B (en) * 2016-06-20 2019-04-12 浙江大学城市学院 Load nanofiber membrane preparation method and the wound dressing application of the core/shell structure of Chinese medicine asiaticosid
CN109381732A (en) * 2017-08-03 2019-02-26 国家纳米科学中心 Electrostatic spinning dressing, preparation method and the application of growth factor-loaded micromolecular inhibitor
CN110772379B (en) * 2019-11-01 2020-11-13 山东汉方制药有限公司 Preparation method of composite nanofiber membrane loaded with nanoenzyme and wound surface application thereof
CN113398312B (en) * 2021-05-27 2022-12-16 华南理工大学 Antibacterial fiber loaded with metal organic framework nanoenzyme and glucose, and preparation method and application thereof

Also Published As

Publication number Publication date
CN113876995A (en) 2022-01-04

Similar Documents

Publication Publication Date Title
Mao et al. Biodegradable and electroactive regenerated bacterial cellulose/MXene (Ti3C2Tx) composite hydrogel as wound dressing for accelerating skin wound healing under electrical stimulation
CN102797074B (en) Method for preparing natural material-liposome composite nanofiber based on electrostatic spinning technology
Dadashzadeh et al. Study of hybrid alginate/gelatin hydrogel-incorporated niosomal Aloe vera capable of sustained release of Aloe vera as potential skin wound dressing
CN102787382A (en) Method for preparing natural material inorganic nanoparticle composite nano-fiber through electrostatic spinning
CN110772379B (en) Preparation method of composite nanofiber membrane loaded with nanoenzyme and wound surface application thereof
CN110747534A (en) Antibacterial polysaccharide fiber material and preparation method thereof
CN113956413A (en) Preparation method of nano composite hydrogel and application of nano composite hydrogel in promotion of diabetic wound healing
CN107149702A (en) A kind of preparation of poly-dopamine modified lithium porous support
CN105088540B (en) A kind of method that nanometer silk fibroin material is prepared based on tryrosinase/polyphenol amboceptoid
CN113876995B (en) Nanofiber membrane for skin wound and preparation method thereof
CN116019973A (en) Nanometer hybridized double-network hydrogel based on nanometer enzyme complex, and preparation method and application thereof
CN114561076B (en) Polyvinyl alcohol gelatin starch hydrogel and preparation method thereof
CN114713150A (en) Novel crosslinking method and application of sodium alginate hydrogel containing graphene oxide
DE19903655A1 (en) Hydrogel comprising protein or enzyme bonded to PEG via urea groups, useful as a dressing for wounds and burns
Li et al. Resveratrol loaded native silk fiber-sericin hydrogel double interpenetrating bioactive wound dressing facilitates full-thickness skin wound healing
CN112159532B (en) Oxygen-containing hydrogel dressing and preparation and application thereof
CN108969757A (en) Load the cerium oxide nano composite hydrogel and preparation method and application of microRNA
CN111388739B (en) Nano silicon dioxide/decomposition enzyme/polycaprolactone composite microsphere and preparation method and application thereof
CN110960723B (en) Preparation method and application of ascidian conductive hydrogel
CN113456610B (en) Manganese dioxide/sericin hybrid nanoparticle for resisting oxidative stress injury and preparation method thereof
KR20200085090A (en) A cellulose nanocrystal derived from rice husk and use of the same
CN114177339A (en) Preparation method of nano-enzyme and glycosaminoglycan composite nanofiber dressing
EP1025860B1 (en) Protein-containing hydrogels
CN109295137B (en) Method for crosslinking modification of microfibril collagen by multi-step continuous enzyme catalysis
EP2470224B1 (en) Collagenous material

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant